Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 7—July 2019
Synopsis

Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear–Negative Drug-Resistant Tuberculosis, China

Fei Huang, Susan van den Hof, Yan Qu, You Li, Hui ZhangComments to Author , Lixia Wang, Miaomiao Sun, Wei Lu, Shuangyi Hou, Tianhua Zhang, Shitong Huan, Daniel P. Chin, and Frank Cobelens
Author affiliations: Chinese Center for Disease Control and Prevention, Beijing, China (F. Huang, Y. Qu, Y. Li, H. Zhang, L. Wang); The Royal Netherlands Tuberculosis Foundation, The Hague, the Netherlands (S. van den Hof); Academic Medical Center, Amsterdam, the Netherlands (S. van den Hof, F. Cobelens); PATH, Beijing (M. Sun); Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China (W. Lu); Hubei Provincial Center for Disease Control and Prevention, Hubei, China (S. Hou); Shaanxi Provincial Institute for Tuberculosis Control and Prevention, Shaanxi, China (T. Zhang); Bill & Melinda Gates Foundation, Beijing (S. Huan); Bill & Melinda Gates Foundation, Seattle, Washington, USA (D.P. Chin)

Main Article

Table 1

Diagnostic algorithm used during baseline and intervention period in study of added value of comprehensive program to provide universal access to care for sputum smear–negative drug-resistant TB, China*

Level Baseline Intervention
County
Light microscopy (Ziehl–Neelsen staining), smear examination, and chest radiograph for all presumptive TB patients
LED fluorescence microscopy (auramine staining), smear examination, and chest radiograph for all presumptive TB patients; culture for all patients with a diagnosis of smear-negative TB
City Culture and phenotypic DST only for patients at 
high risk for MDR TB; culture for smear-positive patients in Zhenjiang Line-probe assay (Genechip; CapitaBio, http://www.capitalbiotech.com) used in Yichang; GenoType 
(Hain Lifesciences, https://www.hain-lifescience.de/ en/company/contact.html) used in Zhenjiang for all bacteriologically confirmed pulmonary TB

*DST, drug susceptibility testing; LED, light-emitted diode; MDR TB, multidrug-resistant tuberculosis; TB, tuberculosis.

Main Article

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external